{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:20:51Z","timestamp":1794406851415,"version":"4.9.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/s1470-2045(26)00337-2","type":"journal-article","created":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:35:49Z","timestamp":1794353749000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial"],"prefix":"10.1016","author":[{"given":"Jiajia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Shigeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemichi","family":"Watari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuyuki","family":"Chiyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanguang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikou","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Hamanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxia","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fugen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(26)00337-2_bib1","doi-asserted-by":"crossref","first-page":"oyae325","DOI":"10.1093\/oncolo\/oyae325","article-title":"Ovarian clear cell carcinoma: open questions on the management and treatment algorithm","volume":"30","author":"Rosso","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/S1470-2045(26)00337-2_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1525-1438.2007.01158.x","article-title":"Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study","volume":"18","author":"Takano","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/S1470-2045(26)00337-2_bib3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2006.12.024","article-title":"Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary","volume":"105","author":"Crotzer","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(26)00337-2_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ygyno.2018.05.029","article-title":"A phase 2 evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group Study (GOG-254)","volume":"150","author":"Chan","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(26)00337-2_bib5","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-18-1244","article-title":"A clinical and molecular phase 2 trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): a study of the Princess Margaret Phase 2 Consortium","volume":"24","author":"Lheureux","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"suppl 4","key":"10.1016\/S1470-2045(26)00337-2_bib6","doi-asserted-by":"crossref","first-page":"A127","DOI":"10.1136\/ijgc-2020-ESGO.223","article-title":"A randomised phase 2 study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium. (NICCC\/ENGOTOv36)","volume":"30","author":"Glasspool","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/S1470-2045(26)00337-2_bib7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/ijgc-2019-000384","article-title":"The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: characterizing the cross-sectional approach to ovarian cancer genetic testing of BRCA (CHARLOTTE)","volume":"29","author":"Enomoto","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/S1470-2045(26)00337-2_bib8","doi-asserted-by":"crossref","first-page":"798173","DOI":"10.3389\/fonc.2021.798173","article-title":"Next-generation sequencing reveals a very low prevalence of deleterious mutations of homologous recombination repair genes and homologous recombination deficiency in ovarian clear cell carcinoma","volume":"11","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"suppl","key":"10.1016\/S1470-2045(26)00337-2_bib9","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1200\/JCO.2025.43.16_suppl.5568","article-title":"Real-world analysis of folate receptor alpha (FR\u03b1; FOLR1) expression in pan-tumor samples from over 6000 patients in the US","volume":"43","author":"Krivak","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(26)00337-2_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00428-011-1169-8","article-title":"PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma","volume":"460","author":"Yamamoto","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/S1470-2045(26)00337-2_bib11","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","article-title":"Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma","volume":"174","author":"Kuo","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/S1470-2045(26)00337-2_bib12","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1038\/ncomms7118","article-title":"Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling","volume":"6","author":"Chandler","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/S1470-2045(26)00337-2_bib13","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3Ca-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(26)00337-2_bib15","doi-asserted-by":"crossref","first-page":"112913","DOI":"10.1016\/j.ejmech.2020.112913","volume":"209","author":"Xiang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/S1470-2045(26)00337-2_bib16","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1038\/s41467-022-34782-9","article-title":"First-in-human phase Ia study of the PI3K\u03b1 inhibitor CYH33 in patients with solid tumors","volume":"13","author":"Wei","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/S1470-2045(26)00337-2_bib17","series-title":"Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of ovarian cancer 2023","year":"2023"},{"key":"10.1016\/S1470-2045(26)00337-2_bib18","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.3802\/jgo.2021.32.e49","article-title":"The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer","volume":"32","author":"Tokunaga","year":"2021","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/S1470-2045(26)00337-2_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2024.02.029","article-title":"Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity","volume":"183","author":"Passarelli","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"suppl 5","key":"10.1016\/S1470-2045(26)00337-2_bib20","doi-asserted-by":"crossref","first-page":"105199","DOI":"10.1016\/j.esmoop.2025.105199","article-title":"Novel regimens for persistent\/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2\/GOG-3051\/BOUQUET phase 2 study results","volume":"10","author":"Ray-Coquard","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/S1470-2045(26)00337-2_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","article-title":"Pembrolizumab in patients with advanced clear cell gynecological cancer: a phase 2 nonrandomized clinical trial","volume":"11","author":"Kristeleit","year":"2025","journal-title":"JAMA Oncol"},{"issue":"suppl","key":"10.1016\/S1470-2045(26)00337-2_bib22","doi-asserted-by":"crossref","first-page":"LBA5500","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500","article-title":"Final results of BrUOG 354: a randomized phase 2 trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas","volume":"42","author":"Dizon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(26)00337-2_bib23","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1158\/1078-0432.CCR-25-0201","article-title":"Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3): a multicenter, randomized, phase 2 trial","volume":"31","author":"Ngoi","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(26)00337-2_bib24","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaoncol.2025.1916","article-title":"Nivolumab and ipilimumab combination treatment in advanced ovarian and endometrial clear cell cancers: a nonrandomized clinical trial","volume":"11","author":"Gao","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/S1470-2045(26)00337-2_bib25","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S1470-2045(24)00437-6","article-title":"Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Peng","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(26)00337-2_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1470-2045(25)00662-X","article-title":"Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial","volume":"27","author":"Ngoi","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(26)00337-2_bib27","doi-asserted-by":"crossref","first-page":"e012805","DOI":"10.1136\/jitc-2025-012805","article-title":"DART\/SWOG\/NCI phase 2 anti-CTLA-4\/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix","volume":"14","author":"Chae","year":"2026","journal-title":"J Immunother Cancer"},{"key":"10.1016\/S1470-2045(26)00337-2_bib28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"key":"10.1016\/S1470-2045(26)00337-2_bib29","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s40264-020-00968-7","article-title":"Interstitial lung disease as an adverse drug reaction in Japan: exploration of regulatory actions as a basis for high reporting","volume":"43","author":"Iwasa","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/S1470-2045(26)00337-2_bib30","doi-asserted-by":"crossref","first-page":"e003093","DOI":"10.1136\/jitc-2021-003093","article-title":"PI3K\u03b1 inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism","volume":"9","author":"Sun","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204526003372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204526003372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:35:52Z","timestamp":1794353752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204526003372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"alternative-id":["S1470204526003372"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(26)00337-2","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(26)00337-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(26)00404-3","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}